FibroBiologics (NASDAQ:FBLG – Get Free Report) and Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.
Risk and Volatility
FibroBiologics has a beta of -0.57, meaning that its share price is 157% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.
Earnings and Valuation
This table compares FibroBiologics and Axsome Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| FibroBiologics | N/A | N/A | -$11.16 million | ($0.48) | -0.54 |
| Axsome Therapeutics | $561.26 million | 13.39 | -$287.22 million | ($4.67) | -31.91 |
FibroBiologics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings for FibroBiologics and Axsome Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| FibroBiologics | 1 | 0 | 3 | 0 | 2.50 |
| Axsome Therapeutics | 1 | 0 | 16 | 1 | 2.94 |
FibroBiologics presently has a consensus target price of $12.33, suggesting a potential upside of 4,625.42%. Axsome Therapeutics has a consensus target price of $179.88, suggesting a potential upside of 20.70%. Given FibroBiologics’ higher possible upside, equities analysts plainly believe FibroBiologics is more favorable than Axsome Therapeutics.
Profitability
This table compares FibroBiologics and Axsome Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| FibroBiologics | N/A | -1,219.18% | -146.48% |
| Axsome Therapeutics | -49.88% | -283.22% | -33.06% |
Insider & Institutional Ownership
81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.8% of FibroBiologics shares are owned by insiders. Comparatively, 22.3% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Axsome Therapeutics beats FibroBiologics on 9 of the 14 factors compared between the two stocks.
About FibroBiologics
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer’s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.
